Forum Agenda

July 23,13:30-17:00

Peptide Drug R&D Frontier Session

Stay tuned

13:30-14:00 GLP‑1 R&D Journey and Outlook
Wang Qinghua, Founder, Chairman & CEO, Guangzhou Innogen Pharmaceutical Group Co., Ltd.

 

14:00-14:20 Precise delivery of anti-tumor molecules
Changqing Su, Chief Scientist, Pharmaceutical Research Institute, Fosun Wanbang Group

 

14:20-14:40 Cyclic Peptide Discovery Integrating mRNA Display and AI
Cui Haifeng, CSO, Shanghai Highline Therapeutics, Inc.

 

14:40-15:00 Recent R&D trends and clinical progresses of small format drug conjugates
Jun Shao, Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co.

 

15:00-15:20 Integrated CMC Solutions to accelerate Peptide Drug Discovery and Development
William Fang, Vice President, Head of Oligonucleotide & Peptide Development, WuXi TIDES

 

15:20-15:40 Break

 

15:40-16:00 AI‑Designed Cyclic Peptide Drugs to Tackle Undruggable Targets
Zhang Genwei, Peptide R&D Lead, XtalPi Holdings Limited

 

16:00-16:20 Screening and Evaluation of Peptide Drugs from GLP‑1 to Multi‑target Agonists
Wang Xinyuan, FAS Manager, China Application, Revvity

 

16:20-17:00 Round Table Dialogue:China's Innovative Peptide Drugs Going Global – Opportunities, Challenges, and the Future
Liu Jiang (Moderator), Vice President & General Manager, Greater China, Revvity
Cao Chunlai, CEO, Federal Biotechnology (Zhuhai Hengqin)
Jun Shao, Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co.
Chen Xiaoxin, Vice President, Guangdong Zhongsheng Pharmaceutical ; Co‑Founder, Chairman & CEO, Guangdong Zhongsheng Ruichuang Biological Technology
Wenjie Xu, Senior Vice President Chief Commercial Officer, Innogen